![Stephen Ma](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Stephen Ma
Financieel Directeur/CFO bij SCILEX HOLDING COMPANY
Vermogen: 15 271 $ op 31-05-2024
Profiel
Stephen Ma is currently working as the Secretary, Chief Financial Officer & Senior VP at Scilex Holding Co. He previously worked as the Director-Finance & Operations at Anwita Biosciences, Inc. Mr. Ma has an undergraduate and graduate degree from San Jose State University.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
SCILEX HOLDING COMPANY
0.01% | 17-05-2024 | 14 140 ( 0.01% ) | 15 271 $ | 31-05-2024 |
Actieve functies van Stephen Ma
Bedrijven | Functie | Begin |
---|---|---|
SCILEX HOLDING COMPANY | Financieel Directeur/CFO | 22-09-2023 |
Eerdere bekende functies van Stephen Ma
Bedrijven | Functie | Einde |
---|---|---|
Anwita Biosciences, Inc.
![]() Anwita Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Anwita Biosciences, Inc. is a clinical stage biopharmaceutical company located in the US. Anwita's lead product, exenokine-21, has been accepted by China NMPA and the US FDA to initiate clinical studies. The American company specializes in the discovery and development of optimized immunotherapeutics for cancer and autoimmune diseases. Anwita's core technology integrates structure-guided accukine cytokine evolution and accubody discovery of full spectrum nanobodies and antibodies, enabling the development of fully optimized cytokine fusions with superior therapeutic potential, favorable safety profile, and great development ability. The private company's unique product portfolio includes half-live extended exenokines, immune cell- or tumor cell-targeting mableukines, and bi-functional duoleukins. The company is also developing other cytokine-based therapeutics and antibody drug conjugates for the potential treatment of various cancers. | Financieel Directeur/CFO | 01-01-2022 |
Opleiding van Stephen Ma
San Jose State University | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
SCILEX HOLDING COMPANY | Health Technology |
Bedrijven in privébezit | 1 |
---|---|
Anwita Biosciences, Inc.
![]() Anwita Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Anwita Biosciences, Inc. is a clinical stage biopharmaceutical company located in the US. Anwita's lead product, exenokine-21, has been accepted by China NMPA and the US FDA to initiate clinical studies. The American company specializes in the discovery and development of optimized immunotherapeutics for cancer and autoimmune diseases. Anwita's core technology integrates structure-guided accukine cytokine evolution and accubody discovery of full spectrum nanobodies and antibodies, enabling the development of fully optimized cytokine fusions with superior therapeutic potential, favorable safety profile, and great development ability. The private company's unique product portfolio includes half-live extended exenokines, immune cell- or tumor cell-targeting mableukines, and bi-functional duoleukins. The company is also developing other cytokine-based therapeutics and antibody drug conjugates for the potential treatment of various cancers. | Health Technology |